GlassScriptPhysician profile
Elizabeth J Crognale
NPI 1396794905
$1,773.48
in general payments reported to CMS, 2019-2025
21 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $375 · 2021: $561 · 2022: $305 · 2023: $115 · 2024: $64.60 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $475.33 | 2019-2025 | Enbrel, Prolia, Evenity |
| Janssen Biotech, INC. | $344.98 | 2020-2022 | |
| Inspire Medical Systems, INC. | $139.28 | 2025 | Inspire |
| Horizon Therapeutics Plc | $103.84 | 2021-2023 | Krystexxa |
| Edwards Lifesciences Corporation | $90.45 | 2019 | |
| Glaxosmithkline, LLC. | $89.06 | 2020-2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $87.79 | 2020-2022 | |
| Pfizer INC. | $85.00 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $65.06 | 2020-2021 | |
| Radius Health, INC. | $46.46 | 2020-2021 | |
| Bioventus LLC | $42.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.09 | 2019-2020 | |
| Abbvie INC. | $29.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $22.44 | 2022 | |
| Daiichi Sankyo INC. | $20.29 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $19.78 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $19.77 | 2024 | Arcalyst |
| Eisai INC. | $15.09 | 2021 | |
| Ucb, INC. | $14.51 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.85 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Crognale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.